Table 1.
Quantification of PKCα mRNA Expression by Quantitative Real-Time PCR in 10 Tumor and Non-tumor Pairs of Gastric Tissues.
Figure 1.
PKCα immunoreactivity in gastric carcinoma of various histologic type and differentiation.
a normal gastric glands showing negative immunostaining, b negative immunostaining in a moderately-differentiated adenocarcinoma of intestinal type, c negative immunostaining in a poorly-differentiated adenocarcinoma of intestinal type, d negative immunostaining of signet-ring cells in a diffuse type adenocarcinoma, e weakly positive immunostaining in a moderately-differentiated adenocarcinoma of intestinal type, f moderately positive immunostaining in a well-differentiated adenocarcinoma of intestinal type, g moderately positive immunostaining in a moderately to poorly-differentiated adenocarcinoma of intestinal type, h moderately positive immunostaining in a diffuse type adenocarcinoma, and i strongly positive immunostaining in a moderately-differentiated adenocarcinoma of intestinal type. Magnification: X200.
Table 2.
PKCα Protein Expression in Gastric Carcinoma and its Correlation with Clinicopathological Parameters.
Table 3.
Uni-Variate Analysis of Prognostic Markers in 215 Patients with Gastric Carcinoma.
Table 4.
Backward Multi-Variate Analysis of PKCα Protein Expression and Other Prognostic Markers in 215 Patients with Gastric Carcinoma.